Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell LymphomaAustin I. Kim, Mark A. Murakami, Victoria Patterson et al.|Blood|2023Cited by 6